Mark that one up to a failure to communicate……
M

Me too Sir, Me too.
M

Again, you must follow the money. Who is losing money because of Chinese APIs? Gilead Sciences. You can be sure Gilead has gotten its greedy hands on some Mesochem ledipasivir and tested it. It probably tested just fine or we would be seeing published results all over the web about the inferior Chinese knock off of its miracle cure.
No, it must have tested perfectly. The next best thing: Get someone who is close to “ground zero”,(Australia), who maybe needed another big grant, who had some credentials, whose done a lot of work for them in the past/present, to make some off-handed remarks about product quality.
Like Dr. Freeman said: “Play the ball, not the man”.
We know what kind of ball Gilead plays with.
M

Well,
We will begin to see if Mesochem is capable of producing high quality ledipasvir in a couple of months, won’t we. What would you expect someone with his background to say? ‘Making the DAAs is like making beer at home….”? No, he is a brilliant man, but a “company man”. I wonder how many shares of Gilead he owns?
Edward J. Gane has received grants and done research for Gilead, served on the advisory boards of AbbVie, Boehringer Ingelheim, Gilead, Janssen, Novartis, Roche, Tibotec; has been a speaker for Gilead, Novartis, Roche, Tibotec; has patents with Gilead.
M